Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty

Shmuel Fuchs, Ran Kornowski, Roxana Mehran, Luis Gruberg, Lowell F. Satler, Augusto D. Pichard, Kenneth M. Kent, Gregg W. Stone, Martin B. Leon

Research output: Contribution to journalArticlepeer-review


Pre-intervention administration of abciximab in patients at "high risk" for coronary angioplasty has been shown to reduce acute and long-term cardiac outcomes. The role of intra-procedural ("rescue") administration of abciximab has not been fully elucidated. We assessed the clinical outcomes associated with rescue administration of abciximab during complex percutaneous coronary interventions. We studied in-hospital and long-term (1-year) outcomes (death, myocardial infarction and target lesion revascularization) of 298 consecutive patients (78% male; age, 62 ± 11 years; 83% with acute coronary syndrome) treated with abciximab for thrombus-containing lesions, sub-optimal angioplasty results, procedural dissections or other complications. Stents were used in 73% of procedures. Procedural success was 97.0% and overall major in-hospital complication rate was 3.0% (death, 1.3%; Q-wave myocardial infarction, 0.7%; and emergent bypass surgery, 1.0%). Most frequent angiographic complications included visible thrombus (17%), dissections (17%), threatened closure (7%), and distal embolization (7%). In-hospital non-Q wave myocardial infarction (defined as CK-MB ≥ 5 times normal) occurred in 31.0%. Out-of-hospital to one-year events included death (1.7%), Q-wave myocardial infarction (2.7%), and target lesion revascularization (15.1%); cardiac event-free survival was 82.9%. We conclude that rescue administration of abciximab is associated with relatively low' in-hospital complications and favorable long-term outcome in patients with sub-optimal angioplasty results and/or procedure-related complications, although peri-procedural non-Q wave myocardial infarction rate is high. A clinical and cost-effective comparison between provisional and rescue administration of abciximab may be warranted.

Original languageEnglish
Pages (from-to)497-501
Number of pages5
JournalJournal of Invasive Cardiology
Issue number10
StatePublished - Oct 2000


  • Abciximab
  • Angioplasty
  • Myocardial infarction
  • Stent


Dive into the research topics of 'Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty'. Together they form a unique fingerprint.

Cite this